ArticleBMC gastroenterology2025
Fibrosis status, extrahepatic multimorbidity and all-cause mortality in 53,093 women and 74,377 men with metabolic dysfunction associated steatotic liver disease (MASLD) in UK biobank.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Large-scale plasma proteomics improves prediction of heart failure among MASLD individuals: A prospective cohort study.American journal of preventive cardiology · 2026Article
- Article
- Burden of MASLD and liver fibrosis: evidence from Phenome India cohort.The Lancet regional health. Southeast Asia · 2026Article
- Albumin-bilirubin score as a practical tool for prognostication in metabolic-associated steatotic liver disease.World journal of hepatology · 2025Article
- Liver fibrosis index and mortality in metabolic dysfunction-associated steatotic liver disease: a Korean cohort study.Scientific reports · 2025Article
- Extrahepatic disease clusters and mortality in people with steatotic liver diseases: a prospective analysis of 64,749 females and 113,587 males in the UK Biobank.BMC medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeople with metabolic-dysfunction associated steatotic liver disease (MASLD) had higher risk of extrahepatic multimorbidity, and fibrosis is the strongest prognostic factor for mortality in MASLD. This study aimed to investigate how fibrosis was associated with multimorbidity and their relationships with all-cause mortality.
methodsWe utilized data from the UK Biobank. MASLD was identified via a Fatty Liver Index ≥ 60 and the presence of cardiometabolic risk factors. The fibrosis-4 (FIB4) score was used to measure liver fibrosis. Multimorbidity was defined as having two or more long-term conditions (LTCs) from a prespecified list of 47 LTCs. Logistic regressions estimated the cross-sectional association between FIB4 scores and multimorbidity prevalence, while Cox models assessed the prospective association between FIB4 scores, multimorbidity and mortality.
resultsWe included 127,470 participants with MASLD (41.7% female, age 57.4 years, 21.3% with multimorbidity, 2.2% with high FIB4 scores). 14,471 deaths were recorded during 13-year follow-up. Compared to low FIB4 scores, high FIB4 scores were associated with 41% higher prevalence of multimorbidity (OR 1.41 (95%CI 1.30-1.54)), and 94% higher all-cause mortality (HR 1.94 (95%CI 1.77-2.13)), while adjusting for multimorbidity reduced the association by 10%, primarily driven by contributions from cardiovascular diseases, extrahepatic cancers, and chronic kidney disease.
conclusionFIB4 scores were positively associated with higher multimorbidity and mortality in MASLD patients. Adjustment for multimorbidity reduced 10% the relationship between fibrosis and mortality, with cardiovascular diseases, cancers and chronic kidney disease contributing notably to this reduction. These findings underscore the importance of managing both fibrosis and multimorbidity in MASLD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.